Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates

European Journal of Medicinal Chemistry

Volumn 42, Issue 1, 2007, Pages 20-29

  Barbaric M ^a   Kralj, M ^b   Marjanovic M ^b   Husnjak, I ^a   Pavelic K ^b   Filipovic Grcic J ^a   Zorc, D ^c   Zorc, B ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antiproliferative effect; Diclofenac; Fenoprofen; Human tumor cell lines; Polyaspartamide; Polymer drug conjugate; Thiomer

Indexed keywords

COPOLYMER; DICLOFENAC; FENOPROFEN; POLY[ALPHA,BETA (N 2 AMINOETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N 2 HYDROXYETHYL DEXTRO,LEVO ASPARTAMIDE)]FENOPROFEN; POLY[ALPHA,BETA (N 2 AMINOETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N 2 HYDROXYETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N 3 MERCAPTO 2 METHOXYCARBONYLPROPYL DEXTRO,LEVO ASPARTAMIDE)]DICLOFENAC; POLY[ALPHA,BETA (N 2 AMINOETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N 2 HYDROXYETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N2 THIOETHYL DEXTRO,LEVO ASPARTAMIDE)]FENOPROFEN; POLY[ALPHA,BETA (N 2 AMINOETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N2 HYDROXYETHYL DEXTRO,LEVO ASPARTAMIDE)]DICLOFENAC; POLY[ALPHA,BETA (N 2 AMINOETHYL DEXTRO,LEVO ASPARTAMIDE]POLY[ALPHA,BETA (N 2 HYDROXYETHYL DEXTRO,LEVO ASPARTAMIDE)]POLY[ALPHA,BETA (N 2 THIOETHYL DEXTRO,LEVO ASPARTAMIDE)]DICLOFENAC; UNCLASSIFIED DRUG;

ADHESION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HELA CELL; HEP 2 CELL; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STRUCTURE ANALYSIS; TENSILE STRENGTH;

ANTINEOPLASTIC AGENTS; ASPARTIC ACID; CELL LINE, TUMOR; DICLOFENAC; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; FENOPROFEN; HUMANS; NYLONS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

EID: 33846678934     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.08.009     Document Type: Article

References (36)

1. Thun M.J., Henley S.J., and Patrono C. J. Natl. Cancer Inst. 94 (2002) 252-266
2. Richter M., Weiss M., Weinberger I., Fürstenberger G., and Marian B. Carcinogenesis 22 (2001) 17-25
3. Gwyn K., and Sinicrope F.A. Am. J. Gastroenterol. 97 (2002) 13-21
4. Husain S.S., Szabo I.L., and Tarnawski A.S. Am. J. Gastroenterol. 97 (2002) 542-553
5. Sivak-Sears N.R., Schwartzbaum J.A., Miike R., Moghadassi M., and Wrensch M. Am. J. Epidemiol. 159 (2004) 1131-1139
6. Kapitanović S., Čačev T., Antica M., Kralj M., Cavrić G., Pavelić K., and Spaventi R. Exp. Mol. Pathol. 80 (2006) 91-96
7. Langman M.J. Clin. Pharmacol. 17 (2003) 393-403
8. Lee C.M., and Maibach H.I. J. Pharm. Sci. 95 (2006) 1405-1413
9. Sood S., Shiff S.J., Yang C.S., and Chen X. Oral Oncol. 41 (2005) 562-567
10. Wang Z., Polavaram R., and Shapshay S.M. Cancer Lett. 198 (2003) 53-58
11. Duncan R. In: Muzykantov V., and Torchilin V. (Eds). Biomedical Aspects of Drug Targeting (2002), Kluwer Academic Publishers, Norwell 193-209
12. Duncan R. Drug Discov. 2 (2003) 347-360
13. Giammona G., Cavallaro G., Fontana G., Pitarresi G., and Carlisi B. J. Controlled Release 54 (1998) 321-331
14. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Clin. Cancer Res. 5 (1999) 83-94
15. Zovko M., Zorc B., Novak P., Tepeš P., Cetina-Čižmek B., and Horvat M. Int. J. Pharm. 285 (2004) 35-41
16. Bernkop-Schnürch A., and Thaler S. J. Pharm. Sci. 89 (2000) 901-909
17. Bernkop-Schnürch A., Kast C.E., and Richter M.F. J. Controlled Release 71 (2001) 277-285
18. Bernkop-Schnürch A., Kast C.E., and Guggi D. J. Controlled Release 93 (2003) 95-103
19. Bernkop-Schnürch A., and Steininger S. Int. J. Pharm. 194 (2000) 239-247
20. Bernkop-Schnürch A., Scholler S., and Biebel R.G. J. Controlled Release 66 (2000) 39-48
21. Kast C.E., and Bernkop-Schnürch A. Biomaterials 22 (2001) 2345-2352
22. Bernkop-Schnürch A., Clausen A.E., and Hnatyszyn M. Int. J. Pharm. 226 (2001) 185-194
23. Bubenik Biličić M., Filipović-Grčić J., Martinac A., Barbarić M., Zorc B., Cetina-Čižmek B., and Tudja P. Int. J. Pharm. 291 (2005) 211-219
24. D. Ballian, M. Zovko, J. Filipović-Grčić, A. Martinac, B. Zorc, in: European Conference on Drug Delivery and Pharmaceutical Technology, Abstract Book, Sevilla, May 10-12, 2004, pp. 101.
25. Johnsen J.I., Lindskog M., Ponthan F., Pettersen I., Elfman L., Orrego A., Sveinbjörnsson B., and Kogner P. Cancer Res. 64 (2004) 7210-7215
26. Takada Y., Bhardway A., Potdar P., and Aggrawal B.B. Oncogene 23 (2004) 9247-9258
27. Butula I., and Jadrijević-Mladar Takač M. Croat. Chem. Acta 73 (2000) 569-574
28. Zorc B., Antolić S., and Butula I. Acta Pharm. 43 (1993) 127-133
29. Zorc B., and Butula I. Acta Pharm. 44 (1994) 103-108
30. Nebioǧlu D., Altuntas G., and Go{combining double acute accent}ker H. J. Fac. Pharm. Gazi 10 (1993) 69-81
31. Zovko M., Zorc B., Lovrek M., and Boneschans B. Int. J. Pharm. 228 (2001) 129-138
32. Zorc B., Ljubić M., Antolić S., Filipović-Grčić J., Maysinger D., Alebić-Kolbah T., and Jalšenjak I. Int. J. Pharm. 99 (1993) 135-143
33. Boyd M.R., and Kenneth D.P. Drug Dev. Res. 34 (1995) 91-109
34. Jarak I., Kralj M., Šuman L., Pavlović G., Dogan J., Piantanida I., Žinić M., Pavelić K., and Karminski-Zamola G. J. Med. Chem. 48 (2005) 2346-2360
35. Zorc B., Maysinger D., Kalčić I., and Butula I. Int. J. Pharm. 123 (1995) 65-70
36. Kralj M., Kapitanović S., Kovačević D., Lukač J., Spaventi S., and Pavelić K. J. Cancer Res. Clin. Oncol. 127 (2001) 173-179